文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

NCCN 指南®洞察：前列腺癌，第 1.2023 版。

NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.

机构信息

1Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

2Stanford Cancer Institute.

出版信息

J Natl Compr Canc Netw. 2022 Dec;20(12):1288-1298. doi: 10.6004/jnccn.2022.0063.

DOI:10.6004/jnccn.2022.0063
PMID:36509074
Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, recurrent, and metastatic disease. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. These NCCN Guidelines Insights summarizes much of the panel's discussions for the 4.2022 and 1.2023 updates to the guidelines regarding systemic therapy for metastatic prostate cancer.

摘要

NCCN 前列腺癌指南针对前列腺癌诊断后的分期和风险评估，并包括局部、区域、复发性和转移性疾病的管理选择。NCCN 前列腺癌专家组每年开会，根据新的临床数据以及 NCCN 成员机构和外部实体的意见，重新评估和更新其建议。这些 NCCN 指南见解总结了专家组在 2022 年 4 月和 2023 年 1 月对指南进行的更新中关于转移性前列腺癌系统治疗的大部分讨论。

相似文献

[1]
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.

J Natl Compr Canc Netw. 2022-12

[2]
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.

J Natl Compr Canc Netw. 2021-2-2

[3]
NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.

J Natl Compr Canc Netw. 2024-4

[4]
Prostate Cancer, Version 1.2016.

J Natl Compr Canc Netw. 2016-1

[5]
Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines.

J Natl Compr Canc Netw. 2013-5-1

[6]
Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.

J Natl Compr Canc Netw. 2013-2-1

[7]
NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

J Natl Compr Canc Netw. 2016-5

[8]
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.

J Natl Compr Canc Netw. 2022-3

[9]
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.

J Natl Compr Canc Netw. 2012-9

[10]
NCCN Guidelines® Insights: Palliative Care, Version 2.2021.

J Natl Compr Canc Netw. 2021-7-28

引用本文的文献

[1]
Treatment Landscape for Older Men With Metastatic Hormone-Sensitive Prostate Cancer in the United States.

Cancer Med. 2025-9

[2]
The relevance of nomograms for prediction of pelvic lymph node metastases in the prostate-specific membrane antigen (PSMA)-PET/CT era.

Curr Urol. 2025-9

[3]
PSMA-Directed Theranostics in Prostate Cancer.

Biomedicines. 2025-7-28

[4]
A randomized study of apalutamide in Chinese patients with non-metastatic castration-resistant prostate cancer.

iScience. 2025-7-18

[5]
Post-marketing surveillance of radium-223 chloride in Japanese patients with castration-resistant prostate cancer with bone metastasis-final analysis of 3-year extended follow-up focusing on bone fractures.

Int J Clin Oncol. 2025-8-8

[6]
Integrating biomarkers and multi-parametric MRI to provide enhanced clinical diagnosis for prostate cancer.

Front Urol. 2023-7-17

[7]
Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis.

BMC Cancer. 2025-7-14

[8]
Structural Retinal and Optic Nerve Changes in Prostate Cancer Patients Receiving Androgen Receptor Pathway Inhibitors: An OCT-Based In Vivo Analysis.

Diagnostics (Basel). 2025-7-1

[9]
Immunotherapy in metastatic prostate cancer.

Ther Adv Med Oncol. 2025-7-3

[10]
Inhibition of Soluble Epoxide Hydrolase Prevents Docetaxel-Induced Painful Peripheral Neuropathy.

Int J Mol Sci. 2025-6-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索